The offering is expected to close on February 19, 2009. On February 12, 2009, the last reported sales price of Geron common stock on the Nasdaq global market was $7.77.
UBS Investment Bank is acting as sole book-running manager for the offering. Lazard Capital Markets is acting as co-manager for this offering.
Geron intends to use the net proceeds from the offering for R&D, clinical trials and general corporate purposes.